SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

          Date of Report (Date of earliest event reported) May 24, 2001

                                   ENZON, INC.
             (Exact name of registrant as specified in its charter)

           Delaware                      0-12957                22-2372868
(State or other jurisdiction of       (Commission             (IRS Employer
        incorporation)                File Number)            Identification)


                20 Kingsbridge Road, Piscataway, New Jersey 08854
               (Address of principal executive offices) (Zip Code)


       Registrant's telephone number, including area code: (732) 980-4500


                                       NA
          (Former name or former address, if changed since last report



Item 5. Other Events

     On May 24, 2001, Enzon Inc. ("Enzon") announced that Arthur J. Higgins will
become its President & Chief  Executive  Officer.  Mr.  Higgins joins Enzon from
Abbott  Laboratories  where he was  President,  Abbott  Pharmaceutical  Products
Division.

     Pursuant to his employment agreement with Enzon, Mr. Higgins will receive a
minimum base salary of $500,000 and an annual bonus equal to between 0% and 200%
of his base salary.  Enzon will grant Mr.  Higgins  options to purchase  800,000
shares of common stock and 25,000 shares of restricted stock.

     Except for the historical  information herein, the matters discussed herein
include  forward-looking  statements  that may  involve  a number  of risks  and
uncertainties.  Actual  results  may vary  significantly  based upon a number of
factors which are described in the Company's  Form 10-K/A,  Form 10-Q's and Form
8-Ks on file with the SEC, including without limitation,  risks in obtaining and
maintaining regulatory approval for indications and expanded indications, market
acceptance  of and  continuing  demand for  Enzon's  products  and the impact of
competitive products and pricing.




                                   SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

Dated: May 24, 2001

                                                  ENZON, INC
                                        ----------------------------------
                                                 (Registrant)



                                    By: /s/ KENNETH J. ZUERBLIS
                                        ----------------------------------
                                        Kenneth J. Zuerblis
                                        Vice President, Finance and Chief
                                          Financial Officer